A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry

References

• Akabane T, Tanaka K, Irie M, et al. (2011). Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372–84.
   PubMed Web of Science ®Google Scholar
• Bode G, Clausing P, Gervais F, et al. (2010). The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods 62:196–220.
   PubMed Web of Science ®Google Scholar
• Choughule KV, Barr JT, Jones JP. (2013a). Evaluation of rhesus monkey and Guinea pig hepatic cytosol fractions as models for human aldehyde oxidase. Drug Metab Dispos 41:1852–8.
   PubMed Web of Science ®Google Scholar
• Choughule KV, Barr JT, Jones JP. (2013b). Evaluation of rhesus monkey and guinea pig hepatic cytosol fractions as models for human aldehyde oxidase. Drug Metab Dispos 41:1852–8.
   PubMed Web of Science ®Google Scholar
• Dalgaard L. (2015). Comparison of minipig, dog, monkey and human drug metabolism and disposition. J Pharmacol Toxicol Methods 74:80–92.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Xiang C, Kang P, Zhou S. (2013). Interspecies variation in the metabolism of zoniporide by aldehyde oxidase. Xenobiotica 43:399–408.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Zhang C, Chen W, et al. (2010). Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641–54.
   PubMed Web of Science ®Google Scholar
• Deguchi T, Watanabe N, Kurihara A, et al. (2011). Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos 39:820–9.
   PubMed Web of Science ®Google Scholar
• Di L, Obach RS. (2015). Addressing the challenges of low clearance in drug research. AAPS J 17:352–7.
   PubMed Web of Science ®Google Scholar
• Diamond S, Boer J, Maduskuie TP, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–85.
   PubMed Web of Science ®Google Scholar
• Dittrich C, Greim G, Borner M, et al. (2002). Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38:1072–80.
   PubMed Web of Science ®Google Scholar
• Dolan ME, Chae MY, Pegg AE, et al. (1994). Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res 54:5123–30.
   PubMed Web of Science ®Google Scholar
• Ellegaard L, Cunningham A, Edwards S, et al. (2010). Welfare of the minipig with special reference to use in regulatory toxicology studies. J Pharmacol Toxicol Methods 62:167–83.
   PubMed Web of Science ®Google Scholar
• Fu C, Di L, Han X, et al. (2013). Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship. Drug Metab Dispos 41:1797–804.
   PubMed Web of Science ®Google Scholar
• Garattini E, Terao M. (2012). The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487–503.
   PubMed Web of Science ®Google Scholar
• Hartmann T, Terao M, Garattini E, et al. (2012). The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos 40:856–64.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Cerny MA, Yang YS, et al. (2014a). Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382. Drug Metab Dispos 42:1751–60.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Obach RS, Dalvie D, Zientek MA. (2013). Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 9:153–68.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Ring BJ, Anderson SR. (2015). Low-turnover drug molecules: a current challenge for drug metabolism scientists. Drug Metab Dispos 43:1917–28.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Albaugh D, et al. (2012). Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40:267–75.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Brown C, et al. (2014b). Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors. Drug Metab Dispos 42:1090–7.
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Demontis S, Barzago MM, et al. (1999). Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone. Biochem J 341: 71–80.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2007). Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59:1177–92.
   PubMed Web of Science ®Google Scholar
• Moriwaki Y, Yamamoto T, Takahashi S, et al. (2001). Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16:745–53.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. (2006). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357–74.
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharm Exp Ther 283:46–58.
   PubMed Web of Science ®Google Scholar
• Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–60.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090–110.
   PubMed Web of Science ®Google Scholar
• Rosen AS, Fournie P, Darwish M, et al. (1999). Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171–5.
   PubMed Web of Science ®Google Scholar
• Strelevitz TJ, Orozco CC, Obach RS. (2012). Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos 40:1441–8.
   PubMed Web of Science ®Google Scholar
• Tang H, Hussain A, Leal M, et al. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–93.
   PubMed Web of Science ®Google Scholar
• Terao M, Romao MJ, Leimkuhler S, et al. (2016). Structure and function of mammalian aldehyde oxidases. Arch Toxicol 90:753–80.
   PubMed Web of Science ®Google Scholar
• Van Der Laan JW, Brightwell J, Mcanulty P, et al. (2010). Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharmacol Toxicol Methods 62:184–95.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu H, Konno Y, Ishii K, et al. (2016). Usefulness of minipigs for predicting human pharmacokinetics: prediction of distribution volume and plasma clearance. Drug Metab Pharmacokinet 31:73–81.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu HH, Weller P, et al. (2011). In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15–24.
   PubMed Web of Science ®Google Scholar
• Zientek M, Jiang Y, Youdim K, Obach RS. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322–7.
   PubMed Web of Science ®Google Scholar
• Zientek MA, Youdim K. (2015). Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos 43:163–81.
   PubMed Web of Science ®Google Scholar